{"id":"ts-1-and-cisplatin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Leucopenia"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL2447941","moleculeType":"Small molecule","molecularWeight":"629.38"},"_fixedAt":"2026-03-30T12:52:48.623153","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TS-1's mechanism of action is primarily through the inhibition of thymidylate synthase, which is necessary for DNA replication. Cisplatin's mechanism of action involves the formation of platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. This results in the inhibition of cancer cell growth and proliferation.","oneSentence":"TS-1 is a prodrug that is converted into 5-fluorouracil (5-FU) in the body, which is then incorporated into DNA and RNA, interfering with DNA replication and transcription, and cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:56.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced gastric cancer"},{"name":"Pancreatic cancer"}]},"_fixedFields":["pubmed(53)"],"trialDetails":[{"nctId":"NCT05065957","phase":"PHASE2, PHASE3","title":"Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2022-03-29","conditions":"Biliary Tract Cancer","enrollment":180},{"nctId":"NCT01286766","phase":"PHASE2","title":"Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":"Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction","enrollment":361},{"nctId":"NCT03382600","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-26","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT06331845","phase":"PHASE2","title":"Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-05-01","conditions":"Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy","enrollment":39},{"nctId":"NCT00915382","phase":"PHASE3","title":"Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-01","conditions":"Advanced Gastric Cancer","enrollment":625},{"nctId":"NCT02182778","phase":"PHASE3","title":"GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2014-07-09","conditions":"Biliary Tract Cancer","enrollment":246},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT01472250","phase":"","title":"A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China","status":"COMPLETED","sponsor":"Peking University","startDate":"2011-11","conditions":"Advanced Gastric Cancer","enrollment":498},{"nctId":"NCT00252161","phase":"PHASE3","title":"A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer","status":"COMPLETED","sponsor":"Haruhiko Fukuda","startDate":"2005-11","conditions":"Gastric Neoplasm","enrollment":316},{"nctId":"NCT01100801","phase":"PHASE2","title":"A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2010-07","conditions":"Recurrent Gastric Cancer","enrollment":90},{"nctId":"NCT01671449","phase":"PHASE3","title":"S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Min-Hee Ryu","startDate":"2012-12","conditions":"Gastric Cancer","enrollment":338},{"nctId":"NCT01284413","phase":"PHASE1, PHASE2","title":"Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":68},{"nctId":"NCT01096199","phase":"PHASE1","title":"A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)","status":"TERMINATED","sponsor":"National University Hospital, Singapore","startDate":"","conditions":"Cancer","enrollment":35},{"nctId":"NCT01388790","phase":"PHASE2","title":"Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT01269255","phase":"PHASE1","title":"A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-12","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT01824004","phase":"PHASE2","title":"Postoperative Chemoradiotherapy With S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2009-04","conditions":"Gastric Cancer","enrollment":46},{"nctId":"NCT01747707","phase":"PHASE2","title":"Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":40},{"nctId":"NCT01645748","phase":"PHASE2","title":"Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2008-10","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT00659113","phase":"PHASE2","title":"S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2008-03","conditions":"Esophageal Cancer","enrollment":32},{"nctId":"NCT00150670","phase":"PHASE3","title":"Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2002-03","conditions":"Gastric Cancer","enrollment":300},{"nctId":"NCT00960349","phase":"PHASE1","title":"Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Gastric Cancer","enrollment":14},{"nctId":"NCT00874328","phase":"PHASE1, PHASE2","title":"A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-10","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"recentPublications":[{"date":"2025 Sep","pmid":"40922714","title":"Pediatric Alpha-Fetoprotein-Producing Gastric Cancer Presenting With Dysphagia and Multiple Liver Tumors.","journal":"Cancer reports (Hoboken, N.J.)"},{"date":"2024 Oct","pmid":"39079466","title":"Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series.","journal":"Clinical genitourinary cancer"},{"date":"2021","pmid":"35444077","title":"[SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION AS A SIDE EFFECT OF CHEMOTHERAPY FOR URACHAL CARCINOMA: A CASE REPORT].","journal":"Nihon Hinyokika Gakkai zasshi. The japanese journal of urology"},{"date":"2019 Nov","pmid":"31302344","title":"Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer.","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"date":"2019 Mar","pmid":"31067849","title":"[A Case of Primary Testicular Mucinous Carcinoma].","journal":"Hinyokika kiyo. Acta urologica Japonica"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TS-1 and cisplatin","genericName":"TS-1 and cisplatin","companyName":"Taiho Pharmaceutical Co., Ltd.","companyId":"taiho-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TS-1 is a prodrug that is converted into 5-fluorouracil (5-FU) in the body, which is then incorporated into DNA and RNA, interfering with DNA replication and transcription, and cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription. Used for Advanced gastric cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}